Inova Labs, LLC. Announces New Senior Vice President Of Operations

AUSTIN, Texas, Jan. 21, 2015 /PRNewswire/ -- Inova Labs Inc., ("Inova Labs"), a leading manufacturer of innovative oxygen therapy solutions, announces the addition of Dale West as the company's new Senior Vice President of Operations. Mr. West is responsible for Manufacturing, Supply Chain, Manufacturing Engineering and Facilities.

New to Inova Labs, West is not new to the executive management industry. His operations experience encompasses an extensive 20-year background in medical devices and the Home Healthcare industry. Prior to joining the company, he held a variety of executive and senior leadership positions with Philips Respironics, Dynamics Inc., and Frito-Lay. As the Vice President of Global Operations and Supply Chain for Respironics, Mr. West was responsible for all Manufacturing, Strategic Sourcing, Logistics, Customer Service, Distribution, After Market Support and Accounts Receivable. He was a key member of the management team that led to the successful sale of Respironics to Philips.

"We are pleased to have Dale join our executive team as he brings with him a wealth of knowledge and experience that is directly applicable to our business. He will play a key role in our company and as we execute on our next phase of growth." John Rush, CEO

Dale West holds a Bachelor of Science in Administrative and Management Science, and a Bachelor of Science in Economics from Carnegie Mellon University.

About Inova Labs
Inova Labs Inc. is a medical device company specializing in the development and commercialization of innovative products for patients with respiratory conditions. Product offerings include the FDA-cleared LifeChoice®, LifeChoice Activox Pro, Sport and 4L Portable Oxygen Concentrators, and the first fully integrated stationary and portable oxygen system concentrator system the Activox DUO2.
www.InovaLabs.com.

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.